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 INTRODUCTION 
 
“By using a plant that has been around for thousands of years, we discovered a new 
physiological system of immense importance.” These were the words of Raphael Mechoulam, 
the “father of Cannabis”, who opened the doors to the chemistry of cannabis by the discovery 
of its psychoactive constituent tetrahydrocannabinol (Δ9-THC).  
The early studies of THC showed its hydrophobic nature, therefore THC was thought to act 
unspecifically by influencing the fluidity of the biological membranes rather than via specific 
interaction with a receptor (Lawrence and Gill 1975). However, it turned out, that its biological 
activity is stereoselective (Jones et al. 1974) and is mediated through the inhibition of cAMP 
accumulation (Howlett and Fleming 1984). These findings suggested the existence of a specific 
receptor, which was identified and cloned in 1990 and named cannabinoid receptor type-1 
(CB1) (Matsuda et al. 1990). By the identification of CB1 it was obvious, that its primary 
function is not the mediation of the effects of phytocannabinoids, therefore different research 
groups started to search for the endogenous ligand of this receptor. The first successful group 
of researchers was Devane and his coworkers, who isolated the first ligand of CB1 and named 
it anandamide after the sanskrit word “ananda”, meaning inner bliss (Devane et al. 1992). This 
was followed by the identification of 2-arachidonoylglycerol (2-AG), the second most 
important endogenous cannabinoid ligand (Mechoulam et al. 1995). These findings encouraged 
the scientist to broaden the spectrum of their knowledge for not only the molecular components 
of the endocannabinoid-mediated intercellular communication, but also for the role of the 
endocannabinoid system in different physiological or pathological processes. Due to this, 
marijuana was known not only as a symbol of hippies and as a recreational drug but also gained 
an outstanding role in the treatment of certain pathological conditions, like increased 
intraocular pressure (Nucci et al. 2007) or atopic dermatitis (Bíró et al. 2009). By different 
morphological, physiological or pharmacological studies researchers successfully 
demonstrated the existence of the components of the endocannabinoid system at peripheral, 
spinal or supraspinal levels of the pain pathway (Agarwal et al. 2007; Drew et al. 2008; 
Herkenham et al. 1991; Pertwee 2001).  
A broad molecular toolbox is responsible for the endocannabinoid-mediated modulation of 
spinal pain processing pathway, from which the presence of CB1 is demonstrated at the first 
relay station of the pain pathway, the dorsal horn of the spinal cord. Hegyi and his coworkers 
demonstrated the existence of CB1 and the major synthesizing enzymes of anandamide and 2-
AG, the NAPE-PLD and DGLα respectively on many cellular elements of the spinal dorsal 
 horn. While CB1 expression can be observed presynaptically mostly on excitatory and 
inhibitory axon terminals or glial cells (Hegyi et al. 2009), the presence of the NAPE-PLD and 
DGLα can be observed on the somatodendritic compartments of neurons but also on glial cells 
(Hegyi et al. 2012). However, the activation and the strength of the cannabinoid modulation is 
not regulated mainly by the mobilisation of the endocannabinoid ligands, but rather by their 
concentration, which is regulated mostly by the rate of their synthesis and degradation. At the 
time of our experiments it was less known about the expression of the degrading enzymes of 
the endocannabinoid ligands, therefore, considering the importance of 2-AG-mediated signal 
transduction pathway in the spinal pain processing, we decided to examine two processes 
responsible for the reduction of the levels of 2-AG. In our experiments we studied the 
expression of the major degrading enzyme of 2-AG, the monoacylglycerol-lipase (MGL) in the 
superficial spinal dorsal horn, and also examined the effects of the spontaneous molecular 
rearrangement of 2-AG on the 2-AG-mediated signal transduction.    
 
  
 MAJOR AIMS 
 
The number of publications dealing with the cannabinoid system has increased rapidly in the 
last 30 years, and our idea of the role of the endocannabinoids in different physiological or 
pathological conditions became more and more complex. In spite of the growing number of 
experimental data in the field of endocannabinoids, our knowledge is still incomplete at many 
points. For instance the cannabinoid mediated control of spinal pain processing, mainly the 2-
AG-mediated modulation of synaptic transmission remains still unclear. At the beginning of 
our experiments there were almost no data about the termination of 2-AG signalling at the level 
of spinal cord, therefore our aim was first: 
- to examine the distribution of the major degrading enzyme of 2-AG, the MGL in the 
superficial spinal dorsal horn and its expression on the cellular elements and axon 
terminals terminating in the superficial laminae. 
Because the expression of MGL on the axon terminals of primary afferents and interneurons 
seemed to be weak, we raised the question if the enzymatic degradation is really the most 
important mechanism of termination of 2-AG signalling. The ability of 2-AG to isomerize was 
well known, however, it was less known about the nature of the end product of this process, 1-
arachidonoyl-glicerol (1-AG). Therefore we have chosen a simple experimental system, the 
COS7 cell line, where the CB1 was overexpressed. Here we wanted to examine: 
- the kinetics of the isomerization of 2-AG 
- the biological activity of 1-AG 
- if 1-AG, the end product of the isomerization of 2-AG has an impact on the 2-AG-CB1 
signal pathway.  
 
  
 MATERIALS AND METHODS 
 
Animals and preparation of tissue sections  
 
Experiments were carried out on nine adult rats (Wistar-Kyoto, 250–300 g, Gödöllő, Hungary), 
two wild-type and one MGL knock-out (Schlosburg et al. 2010) mice. All animal study 
protocols were approved by the Animal Care and Protection Committee at the University of 
Debrecen, and were in accordance with the European Community Council Directives and the 
rules of the Indiana University Institutional Animal Care and Use Committee. The animals 
were deeply anesthetized with sodium pentobarbital (50 mg/kg, i.p.) and transcardially 
perfused with Tyrode’s solution (oxygenated with a mixture of 95 % O2 and 5 % CO2), 
followed by a fixative containing 4 % paraformaldehyde dissolved in 0.1 M phosphate buffer 
(PB, pH 7.4). After the transcardial fixation, the lumbar segments of the spinal cord were 
removed, post-fixed in the original fixative for 1–4 h, and immersed into 10 and 20 % sucrose 
dissolved in 0.1M PB until they sank. In order to enhance reagent penetration the removed 
spinal cord was freeze-thawed in liquid nitrogen. Fifty micrometre thick transverse sections 
were cut on a vibratome, and extensively washed in 0.1 M PB. 
 
Immunohistochemistry 
 
A single immunostaining protocol was performed to study the laminar distribution of MGL. 
Free-floating sections were first incubated in rabbit anti-MGL (diluted 1:30, catalog no.: MGL-
Rb-Af200, Frontier Science Co., Ishikari, Hokkaido, Japan) for 48 h at 4 ℃, and then were 
transferred into biotinylated goat anti-rabbit IgG (diluted 1:200, catalog no.: PK-4001, Vector 
Labs., Burlingame, California, USA) for 12 h at 4 ℃. Thereafter, the sections were treated with 
an avidin biotinylated horseradish peroxidase complex (diluted 1:100, Vector Labs., 
Burlingame, California, USA) for 5 h at room temperature, and the immunoreaction was 
completed with a 3,3-diaminobenzidine (catalog no.: D-5637, Sigma, St. Louis, Missouri, 
USA) chromogen reaction. Before the antibody treatments the sections were kept in 10 % 
normal goat serum (catalog no.: S-1000, Vector Labs., Burlingame, California, USA) for 50 
min. Antibodies were diluted in 10 mM Tris–phosphate-buffered isotonic saline (TPBS, pH 
7.4) to which 1 % normal goat serum (catalog no.: S-1000, Vector Labs., Burlingame, 
California, USA) was added. Sections were mounted on glass slides, dehydrated and covered 
with Permount neutral medium. 
 Double-immunostaining protocols were performed to study the co-localization of MGL 
immunoreactivity with various markers of nociceptive primary afferents, axon terminals of 
putative glutamatergic and GABAergic spinal neurons, astrocytes and microglial cells. Free-
floating sections were first incubated with a mixture of antibodies that contained rabbit anti-
MGL (diluted 1:30, catalog no.: MGL-Rb-Af200, Frontier Science Co., Ishikari, Hokkaido, 
Japan) and one of the following antibodies: (1) guinea pig anti-calcitonin gene-related peptide 
(CGRP) (diluted 1:2,000, catalog no.: T5027, Peninsula Labs, San Carlos, California, USA), 
(2) biotinylated isolectin B4 (IB4) (1:2,000, catalog no.: I21414, Invitrogen, Eugene, Oregon, 
USA), (3) guinea pig anti-vesicular glutamate transporter 2 (VGLUT2) (diluted 1:2,000, 
catalog no.: AB2251, Millipore, Temecula California, USA), (4) guinea pig anti-vesicular 
GABA transporter (VGAT) (diluted 1:600, catalog no.: 131004, Synaptic Systems, Goettingen, 
Germany), (5) mouse anti-glial fibrillary acidic protein (GFAP) (diluted 1:1,000, catalog no.: 
MAB3402, Millipore, Temecula, California, USA), and (6) mouse anti-CD11b (diluted 1:500, 
catalog no.: MCA275G, AbD Serotec, Oxford, UK). The sections were incubated in the 
primary antibody solutions for 2 days at 4 ℃ and were transferred for an overnight treatment 
into the appropriate mixtures of secondary antibodies that were selected from the following: 
goat anti-rabbit IgG conjugated with Alexa Fluor 488 (diluted 1:1,000, catalog no.: A11034, 
Invitrogen, Eugene, Oregon, USA), goat anti-guinea pig IgG conjugated with Alexa Fluor 555 
(diluted 1:1,000, catalog no.: A21435, Invitrogen, Eugene, Oregon, USA), goat anti-mouse IgG 
conjugated with Alexa Fluor 555 (diluted 1:1,000, catalog no.: A21422, Invitrogen, Eugene, 
Oregon, USA), and streptavidin conjugated with Alexa Fluor 555 (diluted 1:1,000, catalog no.: 
S11225, Invitrogen, Eugene, Oregon, USA). Before the antibody treatments the sections were 
kept in 10 % normal goat serum (catalog no.: S-1000, Vector Labs., Burlingame, California, 
USA) for 50 min. Antibodies were diluted in 10 mM TPBS (pH 7.4) to which 1 % normal goat 
serum (catalog no.: S-1000, Vector Labs., Burlingame, California, USA) was added. Sections 
were mounted on glass slides and covered with Vectashield (catalog no.: H-1000, Vector Labs, 
Burlingame, California, USA). 
 
Immunocytochemistry 
 
Transfected COS7 cells were grown on 24-well glass bottom plate and fixed with 4% 
paraformaldehyde dissolved in 0.1 M phosphate buffer for 10 min. Cells were then treated with 
10% normal goat serum for 30 min, followed by an incubation with anti-CB1 antibody (1:2000, 
Cayman Chemicals, Ann Arbor, MI, USA, Cat. No: 10006590) for 2 h. After washing, goat 
 anti-rabbit IgG secondary antibody conjugated with Alexa Fluor 488 (1:1000, Invitrogen) was 
applied for 1 h, then cells were covered with Vectashield-DAPI. Antibodies were diluted in 
PBS (pH 7.4) containing 1% normal goat serum. All incubation steps were carried out at room 
temperature. Imaging of immunostained COS7 cells was carried out with an Olympus IX-81 
inverse microscope attached to a DSD2 an Andor Zyla 5.5 sCMOS camera. Images were 
acquired using a 60 PlanApo N oil-immersion objective (NA: 1.40) and selecting the “high 
signal” disk of DSD2, and processed with Adobe Photoshop CS5. The specificity of anti-CB1 
antibody has extensively been characterized earlier in our laboratory (Hegyi et al. 2009). To 
test the specificity of the immunostaining protocol, transfected COS7 cells were incubated 
according to the immunostaining protocol described above with primary antibodies omitted or 
replaced with 1% normal goat serum. No immunostaining was observed under these 
conditions. 
 
Preembedding immunostaining  
 
A preembedding immunostaining similar to the single immunostaining protocol described 
above was performed to study the cellular distribution of MGL at the ultrastructural level. 
Following extensive washes in 0.1 M PB (pH 7.4), free-floating sections were first incubated 
with rabbit anti-MGL (diluted 1:30, catalog no.: MGL-Rb-Af200, Frontier Science Co., 
Ishikari, Hokkaido, Japan) for 48 h at 4 ℃, than were transferred into biotinylated goat anti-
rabbit IgG (diluted 1:200, catalog no.: PK-4001, Vector Labs., Burlingame, California, USA) 
for 12 h at 4 ℃. Thereafter, the sections were treated with an avidin biotinylated horseradish 
peroxidase complex (diluted 1:100, catalog no.: PK-4001, Vector Labs., Burlingame, 
California, USA) for 5 h at room temperature, and the immunoreaction was completed with a 
3,3-diaminobenzidine (catalog no.: D-5637, Sigma, St. Louis, Missouri, USA) chromogen 
reaction. Before the antibody treatments the sections were kept in 10 % normal goat serum 
(catalog no.: S-1000, Vector Labs., Burlingame, California, USA) for 50 min. Antibodies were 
diluted in 10 mM TPBS (pH 7.4). Immunostained sections were treated with 0.5 % osmium 
tetroxide for 45 min, then dehydrated and flat-embedded into Durcupan ACM resin (catalog 
no.: 44610, Sigma, St. Louis, Missouri, USA) on glass slides. Selected sections were re-
embedded, ultrathin sections were cut and collected on Formvar-coated single-slot nickel grids, 
and counterstained with uranyl acetate and lead citrate. 
 
Confocal microscopy and analysis 
  
Series of 1 µm thick optical sections with 0.5 µm separation in the Z axis were scanned with 
an Olympus FV1000 confocal microscope. Scanning was carried out using a 60 oil-immersion 
lens (NA: 1.42). The confocal settings (laser power, confocal aperture and gain) were identical 
for all sections, and care was taken to ensure that no pixels corresponding to immunostained 
puncta were saturated. The scanned images were processed by Adobe Photoshop CS5 software. 
The co-localization of MGL with the investigated markers was quantitatively analyzed in the 
double-stained sections. A 10x10 standard square grid in which the edge-length of the unit 
square was 4 µm (the whole grid was 40 µmx40 µm in size) was placed onto the regions of 
confocal images corresponding to laminae I–II of the superficial spinal dorsal horn. The proper 
placement of the grid was based on the following criteria: (a) The border between the dorsal 
column and the dorsal horn was easily identified on the basis of the intensity of 
immunostaining. (b) The border between laminae II and III was approximated on the basis of 
previous ultrastructural observations (Molander et al. 1984). Thus, immunoreactivities and co-
localizations were investigated in the most superficial 150 µm thick zone of the dorsal horn 
that had earlier been identified as a layer of the gray matter corresponding to laminae I and II 
in the lumbar segments of the spinal dorsal horn. Profiles that showed immunoreactivity for 
MGL over the edges of the standard grid were counted in the intermediate compartments of 
laminae I and II. The selected profiles were then examined whether they were also 
immunoreactive for the axonal or glial markers. Since MGL is regarded to be a cytoplasmic 
enzyme associating with cell membranes, to define the co-localization values we counted only 
those MGL immunolabeled puncta that were located within the confines of the areas 
immunostained for the marker. The co-localization for all investigated markers was analyzed 
in three animals. The quantitative measurement was carried out in three sections that were 
randomly selected from each animal. Thus the calculation of quantitative figures, mean values 
and standard error of means (SEM), was based on the investigation of nine sections. 
 
Controls and Western Blot analysis 
 
To test the specificity of the antibody raised against MGL, free-floating sections obtained from 
MGL knock-out (Schlosburg et al. 2010) and wild type mice were immunostained according 
to the single immunostaining protocol described above. Sections of MGL knock-out mice were 
negative for MGL, whereas wild-type mice showed a characteristic immunostaining identical 
to that observed in rats. To obtain a more global view about the specificity of the anti-MGL 
 antibody a Western-blot analysis was performed on rats. While the animals were deeply 
anesthetized with sodium pentobarbital (50 mg/kg, i.p.), the lumbar segments of the spinal cord 
were dissected. The dorsal horn was sonicated in 20 mM Tris lysis buffer (pH 7.4) containing 
the following protease inhibitors (mM): EDTA (4.0), EGTA (2.5), PMSF (0.002) benzamidine 
(0.013), pepstatin A (0.004), soybean trypsin inhibitor (0.001), leupeptin (0.001) and aprotinin 
(0.001). After removing cell debris from the sonicated samples with centrifugation (1,500 rcf 
for 10 min at 4 ℃), the supernatant was centrifuged again (12,000 rcf for 20 min at 4 ℃). The 
pellet was re-suspended in lysis buffer containing 1 % Triton X-100 and 0.1 % SDS, and the 
samples were run on 10 % SDS–polyacrylamide gels according to the method of Laemmli 
(1970). The separated proteins were electrophoretically transferred onto PVDF membranes 
(Millipore, Billerica, MA, USA), and the membranes were immunostained according to the 
single immunostaining protocol described above. The immunostaining revealed only one 
immunoreactive band at molecular weight of 33 kDa corresponding to the molecular weight of 
MGL (Dinh et al. 2002). To test the specificity of the immunostaining protocol, free-floating 
sections were incubated according to the single immunostaining protocol described above with 
primary antibodies omitted or replaced with 1 % normal goat serum. No immunostaining was 
observed in these sections. 
The COS7 samples were sonicated in 20 mM TRIS (pH 7.4) lysis buffer supplemented with 
protease inhibitors (4 mM EDTA, 2.5 mM EGTA, 2 mM PMSF, 26 mM benzamidine, 8 mM 
pepstatin A, 2 mg/ml soybean trypsin inhibitor, 2 mg/ml leupeptin, 2 mg/ml aprotinin). The 
cell debris was removed by centrifugation (10 min at 1500 g and 4C), then the supernatant was 
again centrifuged (20 min at 12,000 g and 4℃). The pellet was resuspended in lysis buffer 
containing 1% TRITON X-100 and 0.1% SDS. The samples were stored at -70℃ until use. 
The protein concentration of the samples was determined using the detergent compatible BCA 
assay (Pierce, Rockford, IL, USA). The samples were dissolved in reducing sample buffer (50 
mg protein/lane) and run on 10% SDS-polyacrylamide gels (Laemmli, 1970). The separated 
proteins were electrophoretically transferred onto PVDF membrane (Millipore, Bedford, MA, 
USA). The membranes were blocked with 10% bovine serum albumin (Sigma) in TTBS 
solution (20 mM TRIS, 500 mM NaCl, pH 7.5, 0.05% Tween-20). Membranes were incubated 
with anti-CB1antibody (1:1000, Cayman Chemicals, Ann Arbor, MI, USA, Cat. No: 10006590) 
for 2 h at room temperature. After extensive washing with TTBS the membranes were 
incubated with anti-rabbit IgG-HRP secondary antibody (DakoCytomation, 
Glostrup, Denmark). The labeled protein bands were visualized with 3, 3-diaminobenzidine 
(Sigma). 
 Decomposition of 2-AG in Aqueous Solutions 
 
The endocannabinoid 2-AG and 1-AG were prepared and extracted as described earlier 
(Higuchi et al., 2010; Zhang et al., 2010; Zoerner et al., 2012) with some modifications. Briefly, 
250 ml HBSS containing 0.625 mg/mL anandamide was spiked with either 2-AG (Cayman 
Chemical) or 1-AG (Cayman Chemical) dissolved in acetonitrile in a final concentration of 
0.25 mg/mL in test tubes, and incubated at 37℃ for 1.25, 2.5, 5, or 10 min. Thereafter, the 
samples were frozen in liquid nitrogen and kept there until further processing. Zero time 
samples were spiked with 2-AG after freezing in liquid nitrogen. During sample preparation, 
10 ml trifluoroacetic acid and 1000 ml hexane was added to the frozen samples, which were 
allowed to melt during constant vigorous shaking at 1400 rpm. This allowed the 
endocannabinoids to be transferred to the organic phase immediately after melting. TFA was 
added to stop the base-catalyzed isomerization. Then, the phases were separated by 
centrifugation at 13000 rpm for a minute. An 800 ml aliquot of the hexane layer was evaporated 
to dryness, redissolved in 40 ml acetonitrile containing 0.1% formic acid. Then, 20 ml of this 
solution was injected into the LC/MS. The experiment was performed in three replicates for 
each time point. 
 
Quantification of 1-AG and 2-AG with LC-MS 
 
Changes in the amounts and ratio of 2-AG and 1-AG were determined on a YMC-Triart C18 
(100 mm  3.0 mm, 1.9 mm, 12 nm, YMC Co., Ltd, Kyoto 600-8106, Japan) column, using an 
Accela HPLC system (Thermo Electron Corp., San Jose, CA, USA) eluted with a gradient of 
acetonitrile (A) and water (B) containing 0.1%(V/V) formic acid each. The gradient was from 
60% of A (hold for 2 min) to 90% A over 7 min, hold for 6 min and return to initial conditions 
and hold for 5 min to equilibrate the column. The LC system was coupled with a Thermo LTQ 
XL mass spectrometer (Thermo Electron Corp., San Jose, CA, USA) using positive-ion ESI 
mode as a method of ionization. The ion injection time was set to 100 ms. ESI parameters were 
as follows: spray voltage: 5 kV, source heater temperature: 280℃, capillary temperature of: 
300℃, sheath gas flow: 25 units N2, auxiliary gas flow: 8 units N2. The tray temperature was 
set to 12℃ and the column oven was set to 30℃ to perform the optimal retention of the 
compounds in the reaction mixtures. MS2 product-ion scans were obtained after collision 
induced dissociation with helium as the target gas. Compound identification was based on their 
retention times (tR), HESI mass spectra and MS2 with authentic compounds as references. 1-
 AG and 2-AG levels were determined by LC-ESI-MS/MS in SRM mode and calibration with 
solutions of known concentrations of the analytes extracted for analyses. As an internal 
standard, anandamide was added before each sample extraction. SRM transitions were 379–
287 for 1AG and 2AG and 348–287 for ANA, respectively. For all analytes of interest, recovery 
was calculated to be above 85% which is comparable to that published by Zoerner et al. (2012). 
 
Plasmid Construction 
 
The mammalian expression vector pcDNA3 CB1 was used to overexpress CB1 receptor in 
COS7 cell line [generous gift from Mary Abood, Addgene plasmid # 13391, (Abood et al., 
1997)]. To verify the successful transfection, the red fluorescent protein (RFP) coding 
expression vector CMV-Brainbow-1.0 H (a gift from Joshua Sanes, Addgene plasmid # 18720) 
was co-expressed in the cells under the control of the same CMV promoter as the pcDNA3-
CB1 plasmid (Livet et al., 2007).  
 
Cell Culture and Transfection 
 
COS7 cells (originated from ATCC, kindly provided by the Department of Biophysics, 
University of Debrecen) were grown to 90% confluence (104 cell/cm2) in DMEM (Gibco, 
USA) supplemented with 10% fetal bovine serum (Sigma-Aldrich, USA), 100 U/ml penicillin, 
100 mg/ml streptomycin and 2 mM glutamine (Gibco, USA) under 5% CO2 at 37℃. Prior to 
electroporation, cells were detached from 75 cm2 culturing flasks by incubation with Trypsin-
EDTA (Sigma-Aldrich, USA), pelleted by centrifugation (900 x g for 10 min) and resuspended 
in DMEM (1.9  105 cell/ml). This suspension was used for CB1/RFP co-transfection (20 mg/ml 
CB1 plasmid and 4 mg/ml RFP plasmid) and for control RFP transfection (4 mg/ml RFP 
plasmid). Electroporation was carried out by ECM830 electroporator (BTX, Harvard 
Apparatus, USA) using disposable 2 mm Gap Cuvette (Model No. 620, BTX, Harvard 
Apparatus, USA). The electroporation protocol was as follows: 220 V, two 500 ms width pulses 
with 1 s intervals.  
 
Ca2+ Measurements 
 
Before Ca2+ imaging experiments, transfected COS7 cells were loaded with 1 mM Fluo-8-AM 
in the presence of 0.01% pluronic at room temperature for 30 min. Ca2+ imaging was carried 
 out with an Andor Zyla 5.5 sCMOS camera attached to a differential spinning disk (DSD2, 
Andor Technology) built on an Olympus IX-81 inverse microscope. Using a 10x objective 
(NA:0.25), images of 540 pixels x 306 pixels (corresponding to 1400 mm 790 mm field of 
view, which contained around 200 to 250 cells) were acquired at 15 frames per second with 
Andor iQ3 software. Fluo-8 filled cells were excited at 488 nm and emission was collected at 
520 nm. Acquisition parameters (illumination intensity, exposure time, readout time, frame 
rate) were identical for all experiments. Changes in fluorescence intensities were measured 
over the entire COS7 cell surface by drawing freehand ROIs around single transfected COS7 
cells with sharp RFP signal, that identified unequivocally the entire contour of the transfected 
cell. Ca2+ variations were estimated as changes of the fluorescence signal over baseline 
11(ΔF/F0, where F0 was the average initial fluorescence). A region of interest was considered 
to respond to the application of a compound if ΔF/F0 three times the standard deviation of the 
baseline for at least five consecutive images. Experimental data were analyzed with Microsoft 
Excel 2013 (Microsoft), and FFT filtering to reduce noise and calculation of area under the 
curve (AUC) were performed with Origin Pro 8.0 (Originlab, Northampton, MA, USA). 
Statistical analysis was performed with two-tailed non-parametric Mann–Whitney U test. The 
differences were considered significant when the p level was < 0.05. 
 
  
 RESULTS 
 
Distribution of MGL immunoreactivity in the superficial spinal dorsal horn  
 
To elucidate the distribution of the MGL protein in laminae I–II of the spinal dorsal horn, 
immunostaining for MGL with an antibody directed against a 35 amino acid long segment of 
the enzyme (residues 1–35) was carried out in the rat lumbar spinal cord. Peroxidase-based 
single immunostaining revealed an abundant immunoreactivity for MGL in the lumbar spinal 
cord of rats that was mostly confined to the superficial spinal dorsal horn, laminae I and II of 
the spinal gray matter. Within this area, the inner layer of lamina II (lamina IIi) was even more 
densely stained than the rest of the superficial spinal dorsal horn. Immunostained elements 
appeared as punctate profiles both in the densely and sparsely stained zones.  
 
Co-localization of MGL with markers of nociceptive primary afferents  
 
Laminae I–II of the spinal dorsal horn receives peripheral sensory inputs mostly from 
nociceptive primary afferents (Ribeiro da Silva and De Korninck 2009), which release 
glutamate as synaptic neurotransmitter. A population of nociceptive primary afferents, 
however, also releases neuropeptides in addition to glutamate (Willis and Coggeshall 2004). It 
is well established that most of the peptidergic nociceptive primary afferents express calcitonin 
gene-related peptide (CGRP), whereas non-peptidergic axon terminals selectively binds 
isolectin-B4 (IB4) (Willis and Coggeshall 2004; Ribeiro da Silva and De Korninck 2009). 
Thus, to study the expression of MGL on central axon terminals of peptidergic and non-
peptidergic nociceptive primary afferents we investigated the co-localization of the enzyme 
with CGRP immunoreactivity and IB4-binding. In agreement with previous studies, we 
observed a strong immunostaining for CGRP in laminae I–IIo (Traub et al. 1989; Nasu 1999). 
Investigating the co-localization between MGL and CGRP immunoreactivity, we collected 225 
and 387 profiles immunostained for CGRP and MGL, respectively, and found that 10.0 ± 2.5 
% of MGL immunoreactive puncta were also stained for CGRP, whereas 17.0 ± 3.5 % of CGRP 
immunoreactive axon terminals proved to be immunoreactive also for MGL. Confirming 
earlier observations, IB4-binding labeled a large number of axon terminals in lamina IIi (Guo 
et al. 1999). Despite the strong immunostaining and the substantial spatial overlap between the 
investigated profiles, the co-localization between axon terminals labeled with IB4-binding and 
puncta immunoreactive for MGL was very low. After the investigation of 964 IB4-binding and 
 1090 MGL immunostained profiles, it was found that 1.1 ± 0.3 % of MGL immunoreactive 
puncta were also positive for IB4-binding, whereas 1.1 ± 0.3 % of axon terminals that were 
positive for IB4-binding proved to be immunoreactive also for MGL.  
 
Co-localization of MGL with markers of axon terminals of glutamatergic and GABAergic 
spinal neurons.  
 
Since dorsal rhizotomy leaves VGLUT2 immunoreactivity of the spinal gray matter unaffected, 
it is generally accepted that in immunostaining protocols VGLUT2 can be used as a marker for 
axon terminals of intrinsic spinal excitatory neurons (Alvarez et al. 2004; Brumovsky et al. 
2007). There is also general agreement that vesicular inhibitory amino acid transporter (VGAT) 
is expressed in axon terminals of GABAergic and glycinergic neurons (Chaudhry et al. 1998). 
Therefore, to study the expression of MGL on central axon terminals of putative glutamatergic 
and GABAergic spinal neurons we investigated the co-localization between the enzymes and 
VGLUT2 as well as VGAT immunoreactivities. Confirming results of previous studies (Li et 
al. 2003; Oliveira et al. 2003; Todd et al. 2003; Alvarez et al. 2004; Brumovsky et al. 2007), 
we have revealed a strong punctuate immunostaining for VGLUT2 in laminae I–II. Evaluating 
751 and 1251 profiles immunostained for VGLUT2 and MGL, respectively, we found that 6.3 
± 0.5 % of MGL immunoreactive puncta were also immunostained for VGLUT2, whereas 10.7 
± 1.0 % axon terminals that were positive for VGLUT2 were also immunoreactive for MGL. 
As it has been reported earlier (Polgar and Todd 2008), VGAT immunoreactive axon terminals 
showed a dense and homogeneous distribution in the superficial spinal dorsal horn. 
Investigating the co-localization between MGL and VGAT immunoreactivity, we collected 
609 and 524 profiles immunostained for VGAT and MGL, respectively, and found a minimal 
overlap between VGAT and MGL. Only 2.9 ± 0.8 % of MGL immunoreactive puncta were 
also stained for VGAT, and similarly only 2.4 ± 0.7 % of VGAT immunoreactive axon 
terminals proved to be immunoreactive also for MGL. 
.  
Co-localization of MGL with markers of astrocytes and microglial cells 
 
The existence of bidirectional molecular communication pathways between glial cells and 
neurons has been generally accepted (Araque et al. 2001; Volterra and Bezzi 2002; Nedergaard 
et al. 2003; Haydon and Carmingnoto 2006; Suter et al. 2007; Zhang et al. 2008). It has also 
been demonstrated that CB1s are expressed in microglial cells and astrocytes in various parts 
 of the central nervous system including the dorsal horn of the spinal cord (Rodriquez et al. 
2001; Salio et al. 2002; Cabral and Marciano-Cabral 2005; Navarrate and Araque 2008; Hegyi 
et al. 2009, 2012). Navarrate and Araque (2008) provided direct experimental evidence that 
CB1s on astrocytes can be activated by endocannabinoids released by neurons. MGL is also 
expressed by astrocytes in the dentate gyrus (Uchigasima et al. 2011) and by Bergman glial 
cells in the cerebellum (Tanimura et al. 2012). Thus, because of their potential importance in 
pain processing we investigated the localization of MGL on astrocytes and microglial cells by 
using GFAP and CD11b as markers for astrocytes and microglial cells, respectively. We have 
obtained strong immunolabeling in the superficial spinal dorsal horn for both GFAP and 
CD11b that were identical to that reported earlier (Garrison et al. 1991; Eriksson et al. 1993; 
Molander et al. 1997). Investigating the co-localization between MGL and GFAP 
immunoreactivity, we collected 674 and 794 profiles immunoreactive for GFAP and MGL, 
respectively, and found that 17.4 ± 1.1 % of MGL immunoreactive puncta were also stained 
for GFAP, whereas 20.2 ± 0.9 % of GFAP immunoreactive profiles proved to be 
immunoreactive also for MGL. In contrast to GFAP, we revealed almost a complete 
segregation between MGL and CD11b immunoreactivities. After the investigation of 455 and 
1245 profiles immunostained for CD11b and MGL, respectively, the co-localization analysis 
showed that only 1.0 ± 0.4 % of MGL immunoreactive puncta were also stained for CD11b, 
whereas 2.3 ± 1.4 % of CD11b immunoreactive profiles proved to be immunoreactive also for 
MGL in the spinal dorsal horn.  
 
Ultrastructural localization of MGL immunoreactivity  
 
After revealing a remarkably selective co-localization between MGL and various axonal and 
glial markers, we intended to define the sub-cellular localization of MGL both in axon 
terminals and glial profiles. Furthermore, since in immunofluorescence studies we recovered 
MGL immunoreactive puncta in neural perikarya but not in dendrites, an extensive search for 
MGL immunolabeling in the somato-dendritic compartment of neurons was also carried out. 
In agreement with the results obtained from the colocalization studies, peroxidase reaction 
precipitates labeling MGL were recovered primarily in axons and glial-like processes, but were 
also found in neural perikarya. Regardless of whether the labeled profile was an axon terminal 
or a glia-like profile, immunolabeling was revealed in close association to the plasma 
membrane in a way that the immunoprecipitates always extended into the cytoplasm. In axon 
terminals, the immunolabeling was always recovered in the vicinity of synaptic contacts. Some 
 of the labeled axons contained spheroid, others were full of pleomorphic synaptic vesicles. In 
glia-like processes, the labeling was abundant for MGL. Immunolabeled glia-like processes 
were frequently observed. It was a general finding that the membrane compartment 
immunoreactive for MGL was restricted only to a segment of the glial profile, while the 
adjacent part of the profile was free of labeling. Unfortunately we were not able to define 
whether the detected immunoprecipitates were in astrocytes or microglial cells, since we cannot 
make any distinction between astrocytic and microglial profiles in the electron microscope. In 
perikarya of neurons, immunoprecipitates were associated with cytoplasmic membranes 
resembling membranes of endoplasmic reticulum and Golgi apparatus.  
 
2-AG Rearranges Rapidly to 1-AG in HBSS 
 
Many studies reported rearrangement of 2-AG into 1-AG under ambient conditions. In order 
to simulate the conditions of our in vitro experiments to the highest possible extent, Hank’s 
Balanced Salt Solution (HBSS), a commonly used cell medium (HBSS) was spiked with 2-AG 
and the decomposition curve at 37℃ was determined using LC-MS. The other well-known 
endocannabinoid anandamide, which remains stable during the analytical procedure (Zoerner 
et al., 2012), was successfully used as internal standard to manage inaccuracies of liquid–liquid 
extraction and injections. The peak of anandamide showed no decrease over time. In 
accordance with other publications employing RPMI medium (Rouzer et al., 2002), we found 
that 2-AG is rapidly converted to 1-AG also in HBSS. The half-life of conversion was 16.16 ± 
3.74 min (without serum, extrapolated) and 8.81 ± 2.51 min (with serum), which is within the 
same order of magnitude as reported for other physiological solutions. Differences may come 
from the differences in the media, and from the different initial concentration of 2-AG, since 
Rouzer et al. (2002) used 2 mg/mL (equal to 5 mM), while in our experimental settings the 
concentration was close to the order of magnitude used for the treatment of the cells (0.6 mM). 
The latter is comparable to the concentration of the OH⁻ present, possibly leading to altered 
kinetics of the reaction. The ratio of the two peaks is significantly changed within 2 min. We 
have to add, however, that our experiments were carried out in pure physiological solution, free 
of cells or biological membranes, which helped us to significantly reduce the time frame of 
sample preparation and concomitant artifactual isomerization. This approach is different from 
those publications, in which 1-AG and 2-AG were isolated from biological samples requiring 
lengthy purification steps that provides possibility for post-isolation artifacts (Ferrer et al., 
2003; Suplita et al., 2006). Importantly, acyl migration takes place in any protic solvent 
 (including water) and is actually catalyzed by OH⁻ present in all aqueous solutions at 
physiological pH (Rouzer et al., 2002). Therefore, we assume that 2-AG isomerizes to 1-AG 
on the minute timescale in any water-based media including the one used in the present study. 
In addition, rearrangement of 2-AG is accelerated in the presence of protein, that is likely to 
act as a catalytic surface that increases the reaction speed. Since actually all intracellular or 
extracellular fluids of the living organisms contain proteins, acyl migration is likely to be of 
significance in vivo as well. 
 
Overexpression of CB1 Receptor in COS7 Cells 
 
First, we aimed to establish a simple in vitro model expressing CB1 to study the cellular effects 
of 2-AG and 1-AG. Thus, we transiently transfected COS7 cells with pcDNA3 CB1 by 
electroporation after 5–7 passages to achieve overexpression of CB1 receptor, and verified the 
expression of CB1 by immunocytochemistry. CB1 immunostained puncta could be observed in 
high densities along the cell membrane and also in the cytoplasm of the transfected cells, 
identified by their RFP expression. We also quantified CB1 protein levels 3 days after 
transfection. Western blot analysis with an anti-CB1 antibody confirmed the expression of CB1 
in COS7 cells, and found an approximately 5.6-fold increase in CB1 expression in the 
transfected cells.  
 
Despite Its Conversion into 1-AG, the Biological Effects of 2-AG at Cannabinoid 
Receptors Are Barely Affected on the Minute Timescale 
 
Since 2-AG gradually disappears in HBSS due to isomerization, acyl migration may strongly 
influence the potency of 2-AG. Thus, we examined the effects of decreasing effective 2-AG 
concentration on CB1-induced Ca
2+ transients by loading CB1 transfected COS7 cells with the 
fluorescent Ca2+ indicator Fluo-8-AM and monitoring Ca2+ signals evoked by administration 
of 2-AG. We identified all CB1-transfected cells in the visual field based on the RFP signal, 
and selected cells with sharp and distinct RFP-defined contour for analysis. To allow reliable 
comparison of the experimental data, we performed all Ca2+ imaging with identical settings 
and acquisition parameters. Changes in the fluorescence signal intensity over baseline (ΔF/F0) 
were plotted against time to illustrate alterations in the intracellular Ca2+ concentration. In the 
end of all Ca2+ measurement experiments, we applied 180 mM ATP as final treatment to verify 
viability of cells and obtain maximum Ca2+ response. Cells showing no response to ATP 
 treatment were discarded from further analysis. Values of the AUC of Ca2+ transients evoked 
by ATP were considered as maximal responses for each cell. AUC values of cannabinoid-
evoked Ca2+ signals were also calculated and normalized against responses to ATP by 
expressing CB1-dependent responses as percentage of maximal response. Cells in each well 
were treated only once to avoid desensitization of CB1 and allow registration of consistent 
responses. With these experimental settings, we treated the cells with 2-AG solution, that had 
a 1 mM starting concentration and was administered either immediately (“0-min experiment”), 
or incubated for 2.5, 5, and 10 min at room temperature before application. This amount of 2-
AG is about 50% of the concentration that evokes maximal response, so any change in 2-AG 
levels will be approximately linearly reflected by changes is the Ca2+ transients. Freshly 
prepared and immediately applied 2-AG induced robust transient-like elevation of intracellular 
Ca2+ concentration in CB1 transfected COS7 cells. Two and half minutes after preparation, 2-
AG evoked Ca2+ signals with AUC values practically identical to that of 0-min experiment, 
and an additional incubation of 2-AG solution for 2.5 min caused only a marked diminution of 
Ca2+ responses. Application of 2-AG 10 min after preparation caused a weak and still not 
significant attenuation in cytosolic Ca2+ elevation. 2-AG is readily converted into 1- AG with 
a half-life of 8.8 min. However, the decrease in 2-AG concentration was not reflected in the 
evoked Ca2+ signals, as we detected only an insignificant minor decrease in biological 
responses. 
 
1-AG Concentration-Dependently Increases Intracellular Ca2+ Concentration by 
Activating Cannabinoid Receptors 
 
As the arachidonoyl moiety moves from the 2-position to the 1-position of glycerol, not only 
the effective concentration of 2-AG decreases continuously, but also the amount of 1-AG 
increases gradually in aqueous solutions until the equilibrium between 2-AG and 1-AG is 
reached at approximately 1:9 ratio. Here we investigated if the 1-isomer interacts with CB1 in 
our experimental conditions, and compared its pharmacological properties to those of 2-AG. 
We administered 1-AG solution of various concentration spanning from 10 nM to 100 mM to 
CB1 transfected COS7 cells, and examined if the treatment induced any change in the 
intracellular Ca2+ concentration in our experimental conditions. Starting at low micromolar 
concentration, 1-AG evoked Ca2+ transients with strictly concentration-dependent amplitude 
and AUC values. To compare the potency and efficacy of the two isomers, we repeated the 
above experiment, now by applying various concentration of 2-AG spanning from 10 nM to 
 100 mM. In agreement with earlier observations (Sugiura et al., 1999), 2-AG also induced Ca2+ 
transients even in nanomolar concentration. Concentration-response curve of 1- and 2-AG 
clearly demonstrates that potency of 2-AG (EC50 D 0.6 mM) is threefold higher than that of 
1-AG (EC50 D 1.9 mM), and 2-AG was also found to be more efficacious. To demonstrate 
that 1- and 2-AG induce Ca2+ signals through a CB1 receptor mediated pathway, we applied 
the selective CB1 antagonist AM251. Effects of 1-AG were exclusively mediated by CB1 
receptors, since application of AM251 prevented the raise in intracellular Ca2+ in response to 
10 mM 1-AG in 99.37  0.51% of the cells. Application of AM251 completely abolished 2-AG 
evoked Ca2+ transients also in the majority of the cells, however, 2.33 0.89% of COS7 cells 
still showed responses to 1 mM 2-AG. Preincubation with AM251 caused a pronounced 
decrease in, but could not fully prevent the 2-AG induced raise of, intracellular Ca2+ 
concentration in these cells (data not shown). Preincubation of the cells with AM251 at 5 mM 
caused an apparent drop of the baseline in case of 6.16 ± 0.91 of the cells. This may most 
probably be the result of the inhibition of a basal endocannabinoid tone by AM251, but, as an 
inverse agonist, it may also decrease constitutive CB1 receptor activity. Thus, it is very likely 
that the AM251-induced drop of the baseline is CB1-dependent, but we cannot exclude other 
mechanisms in the background of this phenomenon, such as the inhibition of adenosine A1 
receptors by AM251. 
 
Accumulation of 1-AG Compensates the Decreasing 2-AG Concentration and 
Consequent Drop in Biological Responses 
 
Isomerization of 2-AG creates an interesting situation, since both 1- and 2-isomers of 
arachidonoylglycerol target CB1 and it is very likely that they will compete for the ligand 
binding sites of CB1. However, depending on the relative concentration of the two isomers with 
different potency and ligand binding sites available in the biological environment, combined 
effects of 1-AG and 2-AG may be either additive or antagonistic. We hypothesized that, as 
isomerization proceeds after the moment of 2-AG mobilization, the antagonistic effect of 
accumulating 1-AG becomes gradually more pronounced, resulting in the attenuation of 2-AG 
evoked biological responses. To investigate this possibility, we first calculated the change in 
ratio of the two isomers over 10 min. Based on our measurements, the amounts of 2-AG and 
1-AG change so that, 0.5, 2.6, 4.2, and 9.8 min after dissolving 2-AG in HBSS, their ratio is 
approximately 9:1, 8:2, 6:4, and 5:5, respectively. Thus, in this experiment we treated 
transfected COS7 either with 2-AG alone in a descending serial dilution (0.9, 0.8, 0.6, and 0.5 
 mM), or with a mixture containing increasing quantities of 1-AG (0.1, 0.2, 0.4, and 0.5 mM) 
complementing the decreasing concentration of 2- AG to mimic the progress of isomerization. 
As expected, the drop in effective 2-AG concentration was paralleled by a pronounced 
diminution of evoked Ca2+ transients. Surprisingly, however, effects of 1-AG on 2-AG evoked 
Ca2+ of the two isomers. Although we observed a weak antagonistic effect of 0.1 mM 1-AG 
against 0.9 mM 2-AG, gradually increasing concentration of 1-AG proved to be additive and 
increased Ca2+ signals evoked by declining quantities of 2-AG. The slope of concentration-
response curve of decreasing [2-AG] – increasing [1-AG] pairs mimicked surprisingly well the 
time-dependent minor and not significant changes of 2-AG induced Ca2+ responses. Our 
measurements showed also that the effect of 1-AG on 2-AG dependent cellular responses is 
neutral at approximately at 0.8 mM 2-AG to 0.2 mM 1-AG ratio, that is reached in 2.3 min 
from the moment when 2-AG meets the aqueous medium. 
 
 
  
 DISCUSSION  
 
Endogenous cannabinoids are ubiquitous intercellular messengers playing essential role in a 
variety of physiological and pathological processes. Although the endocannabinoid system has 
been extensively investigated in practically every type of mammalian tissue (Kano et al., 2009; 
Maccarrone et al., 2015), several questions and controversies remain to be solved (Piomelli, 
2014). One of these issues involve the mechanisms that decreases the concentration and 
terminates the effects of the endocannabinoid 2-AG. MGL which accounts for the majority of 
2-AG breakdown in the brain (Beltramo and Piomelli 2000; Cravatt et al. 2001; Blankman et 
al. 2007; Hashimotodani et al. 2007; Vandevoorde and Lambert 2007; Pan et al. 2009; 
Murataeva et al. 2014), has been found in the cytoplasm of presynaptic terminals (Straiker et 
al. 2009; Dinh et al. 2002; Gulya´s et al. 2004). Thus, it is optimally positioned to break down 
2-AG that has engaged presynaptic CB1s. Besides the enzymatic degradative pathways, 2-AG, 
as member of 2-monoglycerol family, is chemically unstable and prone to acyl migration which 
results in the formation of 1-AG (Martin, 1953). This molecular rearrangement generates 
difficulties when quantifying amounts of 2-AG from biological samples (Vogeser and 
Schelling, 2007; Astarita and Piomelli, 2009; Pastor et al., 2014) and interpreting the effects of 
2-AG at cannabinoid and TRP receptors (Zygmunt et al., 2013).   
 
MGL in axon terminals and glial cells 
  
A heterogenous pattern of expression of MGL can be observed in many regions of the central 
nervous system. MGL expression was highly heterogeneous in the cerebellum, being rich 
within parallel fiber terminals but absent in axon terminals of climbing fibers as well as of 
basket cells and stellate neurons. These axon terminals were found to be negative for MGL 
nonetheless they were rich in CB1s (Ohno-Shosaku et al. 2012). Heterogeneous expression of 
MGL has also been found in the dentate gyrus, where MGL is expressed in some GABAergic 
inhibitory terminals of both CB1 positive and negative interneurons (Uchigasima et al. 2011). 
Our present results provide additional proof in support of the partial dissociation of CB1 and 
MGL. In one of our earlier paper we reported that nearly half and more than 20 % of the axon 
terminals of peptidergic and non-peptidergic nociceptive primary afferents, more than one-
third and approximately 20 % of the axon terminals of putative glutamatergic and GABAergic 
spinal interneurons, respectively, were positively stained for CB1 (Hegyi et al. 2009). Here we 
showed that only 17 % of the axon terminals of peptidergic nociceptive primary afferents and 
 10 % of the axon terminals of putative excitatory neurons are immunoreactive for MGL, 
whereas axon terminals of non-peptidergic primary afferents and inhibitory neurons showed 
only a minor degree, if any, immunolabeling for MGL. The remarkably different distribution 
patterns indicate that MGL can be expressed only in a proportion of CB1 positive axon 
terminals in the superficial spinal dorsal horn. Moreover, MGL is almost completely absent in 
CB1 expressing axon terminals of non-peptidergic primary afferents and inhibitory neurons. 
Accepting that MGL-mediated hydrolysis is the primary mechanism for 2-AG inactivation in 
intact neurons (Beltramo and Piomelli 2000; Cravatt et al. 2001; Dinh et al. 2002; Vandevoorde 
and Lambert 2007; Murataeva et al. 2014), we may assume that the magnitude and time course 
of 2-AG mediated retrograde signaling on CB1 positive axon terminals in the superficial spinal 
dorsal horn may vary in a wide range depending on the presence or absence of MGL in the 
axon terminals. According to our finding, 2-AG release may mediate rapidly developing and 
short lasting DSE only in a population of synapses formed by axon terminals of peptidergic 
nociceptive primary afferents and excitatory neurons, whereas 2-AG mediated DSI which may 
appear only in approximately 20 % of synapses established by axon terminals of inhibitory 
neurons (Hegyi et al. 2009) can be a slowly developing and long lasting event in the superficial 
spinal dorsal horn. As another plausible option, MGL positive astrocytes located adjacent to 
synaptic contacts may also substantially participate in the degradation of 2-AG at axon 
terminals that express CB1 but lack MGL.  
A great deal of experimental data indicates that, in addition to neurons, 2-AG is produced and 
inactivated by glial cells (Walter and Stella 2003; Walter et al. 2004; Stella 2009). Bergman 
glial cells in the cerebellum (Tanimura et al. 2012), astrocytes in the dentate gyrus (Uchigasima 
et al. 2011) and hypothalamus (Di et al. 2013), as well as microglial cells in culture (Witting et 
al. 2004) have been shown to express MGL. Due to their close association with synaptic 
contacts, astrocytes can control extracellular neurotransmitter levels by forming a physical 
diffusion barrier and by mediating transmitter uptake (Piet et al. 2004;Gordonet al. 2009; 
Tasker etal. 2012; Di et al. 2013). As we presented here, similarly to the dentate gyrus and 
hypothalamus (Uchigasima et al. 2011; Tanimura et al. 2012), a population of astrocytes, but 
not microglial cells, express MGL also in the superficial spinal dorsal horn. Astrocytes, 
therefore, may provide dynamic control over the extracellular spatial distribution of stimulus-
evoked 2-AG under different physiological conditions (Di et al. 2013). The perisynaptic 
buffering of 2-AG by astrocytes, can restrict 2-AG action to those CB1 expressing axon 
terminals of nociceptive primary afferents and excitatory spinal neurons, the activation of 
which evoke postsynaptic 2-AG release (Di et al. 2013). However, in case of changing 
 functional conditions, which results in the attenuation of astrocytic buffering, 2-AG can diffuse 
out from its site of release and can act heterosynaptically (Kano et al. 2009; Uchigasima et al. 
2011; Tanimura et al. 2012; Di et al. 2013). It is important to note that microglial cells are 
essential constituents of the spinal endocannabinoid system, since they express CB1 (Hegyi et 
al. 2009) and may also release 2-AG and anandamide (Hegyi et al. 2012). Surprisingly, 
however, we were unable to confirm the presence of MGL on these cells. Although our group 
has not investigated alternative enzymatic routes of 2-AG degradation, we assume, that in 
spinal microglial cells - similarly to BV-2 cells - the ABHD6 is responsible for this process 
(Marrs et al. 2010; Muccioli et al. 2007). Our findings verifying the differential expression of 
MGL in astrocytes and microglial cells suggest that these  cells may play different roles in the 
degradation of endocannabinoids. Therefore, their roles in the  endocannabinoid-mediated 
modulation of spinal pain processing, and the induction and maintenance of pathological pain 
can also be very  different.  
Based on our data, the number of MGL positive synapses is much lower than those positive for 
CB1 suggesting that in synapses carrying CB1 but lacking MGL, either a different mechanism 
is  responsible for the degradation of 2-AG, or the effects induced by 2-AG are prolonged.  
We have to mention however, that nearly at the same time we published our paper about the 
spinal expression of MGL, an other hungarian scientific group also demonstrated the presence 
of MGL in the superficial spinal dorsal horn, and the results of their experiments, that overlap 
with our studies confirmed our observations (Horváth et al. 2014).   
 
The role of acylmigration in the degradation of 2-AG 
 
Here we investigated the kinetics of 2-AG isomerization into 1-AG and found that acyl 
migration is a rapid molecular rearrangement with a half-time of 16.16 min in HBSS and 8.8 
min in HBSS containing 10% serum at 37C. Although our measurements were carried out in 
cell-free physiological solutions, these results may indicate the biological relevance of 2-AG 
isomerization in certain cellular environments, since 2-AG degrading hydrolases decrease the 
amounts of 2-AG with a halflife of 19–28 min depending on the cell density (Di Marzo et al., 
1999). In that case, acyl migration and 1-AG formation seems to be approximately two times 
faster than enzymatic inactivation of 2-AG. Importantly, isomerization does not have an impact 
on the findings of the cited paper, since 1- and 2-monoacyglycerols are equally accepted by the 
investigated hydrolases, and their catabolism results in the formation of the same end-products 
(Tornqvist and Belfrage, 1976; Di Marzo et al., 1999). In many other physiological conditions, 
 however, where the half-life of 2-AG signaling is shorter than the rate of isomerization, 
formation of 1-AG is unlikely to play physiologically relevant role. This may be the case in 2-
AG mediated retrograde synaptic transmission, where the half-lives of depolarization induced 
suppression of excitation of inhibition has been shown to fall in the 15–40 s range (Kano et al., 
2009). Earlier studies demonstrated, that isomerization of 2-AG depends primarily on the pH 
and partly on the ionic strength of the milieu, and found faster acyl migration with a half-life 
of 10 min in serum-free and 2.3 min in serum-supplemented RPMI medium at 37℃ (Rouzer 
et al., 2002). Although we cannot fully explain this difference, we assume that the faster 
isomerization may be the result of the richer and well supplemented RPMI medium used in the 
cited study. The somewhat slower chemical transformation which we found still indicates that, 
regardless of the presence of monoacylglycerol degrading enzymes, release of 2-AG into 
aqueous extracellular space leads to the formation and possibly to the temporary accumulation 
of 1-AG, which gives special importance to bioactivity or inactivity of 1-AG at cannabinoid 
receptors. Therefore, we next investigated if 1-AG has any CB1 mediated biological activity, 
and found that 1-AG transiently increases intracellular Ca2+ concentration in a dose dependent 
manner. This finding, in good agreement with earlier and frequently overlooked studies 
(Sugiura et al., 1999), demonstrates that 1-AG is indeed a bioactive molecule that activates 
CB1. EC50 of 1-AG was found to be one order of magnitude higher than that of 2-AG, and 2-
AG was more efficacious in producing biological responses in CB1 transfected COS7 cells. 
However, 1-AG can also be considered as a high efficacy agonist at CB1 receptor, and 
isomerization of 2-AG, therefore, does not represent a non-enzymatic inactivation mechanism, 
but yields another bioactive molecule activating the same receptors as its precursor. We have 
to add, however, that during physiological conditions, a cellular environment may never reach 
such a high concentration of 1-AG that evokes maximal response. Thus, 1-AG is likely to 
incompletely activate CB1 receptors. Acyl migration following 2-AG release creates a rather 
unique situation, when the monoacylglycerol concentration is relatively constant, but the ratio 
of the two isomers changes rapidly as 2-AG is gradually replaced by 1-AG, and the two isomers 
may compete for ligand binding sites of CB1. Therefore, we next studied the biological 
consequences of this process by preparing mixtures of the two isomers in a ratio that simulates 
the time-dependent change in their relative quantities. The moderate and not significant 
diminution of effects of 2-AG on Ca2+ signaling over time was surprisingly similar to that of 
the appropriate artificial mixtures of the two isomers representing given time point of 
isomerization. Importantly, results of both experiments were significantly different from the 
more pronounced decline evoked by decreasing quantities of 2-AG alone indicating, that 
 accumulating 1-AG stabilizes the cannabinoid signal and masks the biological consequences 
of isomerization-related drop in 2-AG concentration. This may explain why chemical 
instability of 2-AG did not have any obvious impact on experimental settings with 5–10 min 
or even longer time frames (Szabo et al.,2006; De Luca et al., 2014; Stanley and O’Sullivan, 
2014; Griebel et al., 2015), and it is also very likely that such measurements result in data 
mirroring at least partly or mostly effects of 1-AG. Bioactivity of 1-AG at CB1 and its ability 
to effectively compensate the rapid elimination of 2-AG may represent an essential mechanism 
in maintaining long-lasting effects of 2-AG and also basal endocannabinoid tone. However, 
our results and interpretation have certain limitations. We carried out experiments on 
transfected cell cultures, which may be different from most in vivo conditions in terms of cell 
physiology and metabolism, intercellular connections and extracellular environment. For 
instance, various enzymes degrading monoacylglycerols may effectively modify the ratio of 
the two isomers. MGL equally accepts both 1-AG and 2-AG, whereas ABHD6 and ABHD12 
show preference to 1-AG over the 2-isomer (Navia-Paldanius et al., 2012). Thus, differential 
expression of these hydrolases in various types of cells and tissues may result in highly different 
1-AG/2-AG ratios. Moreover, 2-AG release into aqueous extracellular space is frequently 
mentioned as an important step of cannabinoid signaling, but its proper mechanism is poorly 
understood (Bisogno et al., 1997; Sugiura and Waku, 2000; Di Marzo et al., 2005), and is 
further complicated by lateral diffusion, i.e., 2-AG is dissolved in, and travels along cell 
membranes, which may delay or prohibit acyl migration (Makriyannis et al., 2005; Hurst et al., 
2010). Thus, biological processes associated with 2-AG release may represent composite 
effects of various mixtures of the 1- and 2- isomers. Fast endocannabinoid signaling, such as 
homosynaptic retrograde neurotransmission is most likely dominated by 2-AG, whereas in case 
of prolonged effects of cannabinoids, like tonic cannabinoid receptor activation (Sagar et al., 
2010), participation of 1-AG in stabilizing the net cannabinoid signal and maintaining CB1 
activation may be more prominent. This latter possibility opens the question if prolonged 
incubation with the two isomers induce differential degrees of CB1 desensitization which may 
further diversify the outcome of isomerization. Importantly, commercially available 2-AG 
preparations already contain approximately 10% 1-AG, therefore the isomerization process 
starts at 9:1 ratio. Although 1-AG masks the isomerization-associated drop in 2-AG 
concentration, the strength of the evoked biological responses will necessarily reflect the 
effects of various mixtures of the two isomers in only several minutes. Investigators should be 
aware of acyl migration in experiments employing 2-AG, and choose carefully a time frame 
 short enough to prevent formation of 1-AG so that the results can reliably be associated with 
2-AG. 
 
  
 SUMMARY 
The proper functioning of the nociceptive pain processing pathway is regulated by certain 
mechanisms, among others by the endocannabinoid system. This is supported by the 
presence of the components of the endocannabinoid system in the regions of the central 
nervous system responsible for pain processing, also in the dorsal horn of the spinal cord, the 
first relay station of the pain pathway. Our earlier studies demonstrated the presence of the 
cannabinoid receptor type-1 (CB1) and the synthesising enzyme of 2-AG, the diacilglycerol-
lipase ⍺ (DGL⍺) in the superficial laminae of the spinal dorsal horn, however, less is known 
about the spinal expression of monoacilglycerol-lipase (MGL), the enzyme responsible for the 
degradation of 2-AG. Therefore our aim was first to study the cellular and ultrastructural 
distribution of the MGL in the superficial laminae of spinal dorsal horn in rodents by 
immunohistochemical studies at the light- and electron microscopic level.  
Our results suggest, that nearly 20% of the peptidergic primary afferent axon terminals, 10% 
of the axon terminals of excitatory interneurons and 20% of astrocytes are positive for MGL in 
laminae I. and II. However, the presence of MGL can be demonstrated in less than 3% of the 
axon terminals of non-peptidergic primary afferents and inhibitory interneurons and also 
microglial cells. This is a surprising finding if we consider the presence of CB1 in the majority 
of these structures which suggests, that they are under cannabinoid control. In this case, for the 
termination of the action of 2-AG has to be mediated by a different mechanism than the 
enzymatic route via MGL.  
In the elimination of 2-AG we have to consider the termodinamical instability of 2-AG, by 
whichit is prone to spontaneous molecular rearrangement, during which the arachidonoil 
moiety of the molecule moves from the 2. carbon atom to the 1. carbon atom. This process is 
known as acylmigration and catalyses the formation of a termodinamically more stable 
molecule, 1-AG. In this way acylmigration can be a modulator of endocannabinoid signalling, 
since it can support the elimination of 2-AG signalling if it doesn't have biological activity. 
However, due to the structural similarity of 1-AG to 2-AG it can activate CB1, in this way the 
isomerization of 2-AG can be a fine modulator of the endocannabinoid signalling, where the 
strength and duration of 2-AG induced responses can be influenced by the forming 1-AG.  
Therefore in our further experiments we studied the biological activity of 1-AG in COS-7 cell 
line, transfected with CB1 and also examined if the continuously accumulating 1-AG can affect 
the 2-AG signaling. Our results suggest, that 1-AG generates Ca2+ transients through a CB1-
dependent manner, therefore it can be considered as a bioactive metabolite and the agonist of 
CB1. It is important to note however, that one order of magnitude higher concentration of 1-
AG is necessary to evoke the same response as 2-AG does, so 1-AG is a weaker agonist of the 
CB1 receptor. Our results further demonstrate, that in low concentration 1-AG is a competitive 
antagonist of 2-AG, but the continuously increasing concentration of 1-AG seems to have an  
additive effect, since besides the decreasing concentration of 2-AG the forming 1-AG 
effectively compensated the weakening effects of 2-AG.  
Our results indicate, that 1-AG, that is formed during the isomerisation of 2-AG is a bioactive 
ligand and is primarily responsible for the mediation of long lasting endocannabinoid-mediated 
processes. Because the spinal expression of MGL is lower than the expected, and the 
acylmigration is not a true inactivation process of 2-AG signalling we have to assume, that in 
the superficial laminae of the spinal dorsal horn other degradative routes serve for the 
termination of 2-AG mediated endocannabinoid signalling.    
 
  
  
  
     
 
